Featured News

Exelixis Announces Start of Phase 1 Trial of Cabozantinib in Combination with Nivolumab or Nivolumab Plus Ipilimumab in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors SOUTH SAN FRANCISCO, Calif. — (BUSINESS WIRE) — Jul. 13, 2015 — Exelixis, Inc. (NASDAQ:EXEL) today announced the initiation of a phase 1 trial of cabozantinib in combination with nivolumab alone or in combination with nivolumab plus ipilimumab in patients with advanced/metastatic urothelial (bladder) and other genitourinary tumors…. More →

Dr. W. Marston Linehan, Chief of Urologic Oncology at the National Cancer Institute (NCI) recently spoke to the advocacy group that gathered in Washington, DC, for ACKC’s annual Campaign for Research Funding. Dr. Linehan spoke to the group in layman’s terms regarding the recent advances in kidney cancer research (see video below). He described the strong sense of hope and excitement for major breakthroughs that may be coming as researchers are making significant progress regarding… More →

Nivolumab Approved for Another Cancer

by Jay Bitkower on March 7, 2015

On March 4, 2015, the FDA approved the Bristo-Myers Squibb (BMS) immunotherapy drug nivolumab (Opdivo) for use in non-small cell lung cancer (NSCLC) patients for whom other drugs have failed. The approval was based on interim results in a Phase III trial testing nivolumab, at 3 mg/kg, against docetaxel, a chemotherapy drug. Nivolumb was found to have extended overall survival (OS) by three months over docetaxel, giving patients on nivolumab a median OS of 9.2… More →


by Jay Bitkower on February 16, 2015

A recent segment on NPR, segment, reported about a study, involving tens of thousands of participants over a 50-year period, by Dr. Barbara Cohn from UC Berkeley looking into the effect of environmental factors on the development of breast cancer in mothers and their children. Dr. Cohn plans to map out what’s called the “exposome” (see exposome), which is a map of the exposure of an individual over his or her lifetime to various environmental and… More →

Rebound and Resistance in Targeted Therapies

by Bryan Lewis on December 24, 2014

John Ebos of Roswell Park Cancer Institute was granted a Career Development Award by the Congressionally Directed Medical Research Programs of the Department of Defense (DoD) to study, using a pre-clinical model, rebound and resistance to targeted therapies in RCC. This two-year grant was funded at $602,996 in Fiscal Year 2013 (the latest award year). This project is designed to answer a number of important questions, in regard to targeted therapy, that have not been… More →